Tomasz Siminiak

Tomasz Siminiak

Auto-generated profile, based on publicly available information

Tomasz Siminiak

Poznan University of Medical Sciences, HCP Medical Center, Poznan, Poland

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2005 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TSTomasz Siminiak
Tomasz Siminiak
DFDorota Fiszer
Dorota Fiszer
OJOlga Jerzykowska
Olga Jerzykowska
BGBeata Grygielska
Beata Grygielska
NRNatalia Rozwadowska
Natalia Rozwadowska
Maciej KurpiszMaciej Kurpisz
Maciej Kurpisz
Aims Several experimental studies and the initial clinical experience have shown that autologous skeletal myoblast transplantation into the area of post-infarction left ventricular injury results in an increase in segmental contractile performance. This phase I clinical trial was designed to assess the feasibility and safety of autologous skeletal myoblast transplantation performed via a percutaneous trans-coronary-venous approach in patients with post-infarction left ventricular dysfunction. Methods and results Ten patients with heart failure and presence of an akinetic or a dyskinetic post-infarction injury with no viable myocardium were included in the study. Skeletal myoblasts were obtained from a biopsy specimen and grown in cell culture. Patients were treated with prophylactic amiodarone infusion before and during the procedure, except one patient. Skeletal myoblast transplantations were performed uneventfully in nine patients using the TransAccess® catheter system under fluoroscopic and intravascular ultrasound guidance. In one patient, the procedure was not performed because of the inability of appropriate coronary sinus guiding wire positioning across venous valve. In five patients, the anterior interventricular vein and in four patients, the middle cardiac vein were used to access the myocardium. Two to four intramyocardial injections 1.5–4.5 cm deep were performed in each patient, delivering up to 100 million cells in 0.4–2.5 mL of saline. During 6 months follow-up, New York Heart Association class improved in all patients and ejection fraction increased 3–8% in six out of nine cases. Conclusion These data suggest the feasibility and procedural safety of myoblast transplantation performed via the trans-coronary-venous approach using the TransAccess catheter system.

11 June 2014 in Polish Heart Journal
Verified
Journal Article
Closed access
Rafał DankowskiRafał Dankowski
Rafał Dankowski
ABArtur Baszko
Artur Baszko
MSMichael Sutherland
Michael Sutherland
LFLudwik Firek
Ludwik Firek
PKPiotr Kałmucki
Piotr Kałmucki
TSTomasz Siminiak
Tomasz Siminiak
Structural heart disease, including valvular disease as well as congenital defects, causes important alterations in heart anatomy. As a result, individualised planning for both surgical and percutaneous procedures is crucial for procedural optimisation. Three dimensional (3D) rapid prototyping techniques are being utilised to aid operators in planning structural heart procedures. We intend to provide a description of 3D printing as a clinically applicable heart modelling technology for the planning of percutaneous structural heart procedures as well as to report our first clinical use of a 3D printed patient-specific heart model in preparation for a percutaneous mitral annuloplasty using the Mitralign percutaneous annuloplasty system. Retrospectively gated, contrast enhanced, multi-slice computed tomography (MSCT) scans were obtained. MSCT DICOM data was analysed using software that creates 3D surface files of the blood volume of specific regions of interest in the heart. The surface files are rendered using a software package that creates a solid model that can be printed using commercially available stereolithography machines. The technique of direct percutaneous mitral annuloplasty requires advancement of a guiding catheter through the aorta, into the left ventricle, and requires the positioning of the tip of the catheter between the papillary muscles in close proximity to the mitral annulus. The 3D heart model was used to create a procedural plan to optimise potential device implantation. The size of the deflectable guiding catheter was selected on the basis of the patient's heart model. Target locations for annulus crossing wires were evaluated pre-procedurally using the individual patient's 3D heart model. In addition, the ability to position the Bident Catheter at the appropriate locations under the mitral annulus as well as the manoeuvrability between the papillary muscles were analysed on the heart model, enabling safe completion of the procedure, which resulted in a significant reduction in mitral regurgitation. 3D printing is a helpful tool in individualised planning for percutaneous structural interventions. Future studies are warranted to assess its role in preparing for percutaneous and surgical heart procedures.

1 August 2009 in The American Journal of Cardiology
Verified
Journal Article
Closed access
TSTomasz Siminiak
Tomasz Siminiak
UHUta C. Hoppe
Uta C. Hoppe
JSJoachim Schofer
Joachim Schofer
MHMichael Haude
Michael Haude
JHJean-Paul Herrman
Jean-Paul Herrman
RBRichard Van Bibber
Richard Van Bibber

13 December 2013 in Polish Heart Journal
Verified
Journal Article
Closed access
TSTomasz Siminiak
Tomasz Siminiak
Rafał DankowskiRafał Dankowski
Rafał Dankowski
ABArtur Baszko
Artur Baszko
CLChristopher Lee
Christopher Lee
LFLudwik Firek
Ludwik Firek
AGAdam Groothuis
Adam Groothuis
Functional mitral regurgitation (FMR) is known to contribute to a poor prognosis in patients with heart failure (HF). Current guidelines do not recommend cardiac surgery in patients with FMR and impaired ejection fraction due to the high procedural risk. Percutaneous techniques aimed at mitral valve repair may constitute an alternative to currently used routine medical treatment. To provide a description of a novel percutaneous suture-based technique of direct mitral annuloplasty using the Mitralign Bident system, as well as report our first case successfully treated with this method. A deflectable guiding catheter is advanced via the femoral route across the aortic valve to the posterior wall of the ventricle. A nested deflectable catheter is advanced through the guide toward the mitral annulus that allows the advancement of an insulated radiofrequency wire to cross the annulus. The wire is directed across the annulus in a target area that is 2-5 mm from the base of the leaflet into the annulus, as assessed by real-time 3D transoesophageal echocardiography. After placement of the first wire, another wire is positioned using a duel lumen bident delivery catheter, which provides a predetermined separation between wires (i.e. 14, 17 or 21 mm). Each wire provides a guide rail for implantation of sutured pledget implants within the annulus. Two pairs of pledgets are implanted, one pair in each of the P1 and P3 scallop regions of the posterior mitral annulus. A dedicated plication lock device is used to provide a means for plication of the annulus within each pair of the pledgets, and to retain the plication by delivering a suture locking implant. The plications result in improved leaflet coaptation and a reduction of the regurgitant orifice area. A 60-year-old female with diagnosed dilated cardiomyopathy, concomitant FMR class III and congestive HF was successfully treated with the Mitralign Bident system. Two pairs of pledgets were implanted resulting in an improvement of transoesophageal echocardiographic parameters, including proximal isovelocity surface area radius (0.7 cm to 0.4 cm), effective regurgitant orfice area (0.3 cm² to 0.1 cm²) and mitral regurgitant volume (49 mL to 10 mL). Percutaneous mitral annuloplasty with the Mitralign Bident system is feasible. Future clinical trials are needed to assess its safety and efficacy.

9 September 2003 in Circulation
Verified
Journal Article
Open access
PDF file
TSTomasz Siminiak
Tomasz Siminiak
Maciej KurpiszMaciej Kurpisz
Maciej Kurpisz

1 June 2020 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
JLJanusz Lipiecki
Janusz Lipiecki
DKDavid Kaye
David Kaye
KWKlaus K. Witte
Klaus K. Witte
MHMichael Haude
Michael Haude
SKSamir Kapadia
Samir Kapadia
TSTomasz Siminiak
Tomasz Siminiak